Each filer's latest filing for 28106W103 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Commodore Capital LP
13G
|
9.9% |
6/2/2026
Event 5/26/2026
|
||
| Commodore Capital LP | 9.9% | |||
| Commodore Capital Master LP | 9.9% | |||
| Robert Egen Atkinson | 9.9% | |||
| Michael Kramarz | 9.9% | |||
|
TCG Crossover GP III, LLC
13G
|
9.9% |
6/3/2026
Event 5/27/2026
|
||
| TCG Crossover GP III, LLC | 9.9% | |||
| TCG Crossover Fund III, L.P. | 9.9% | |||
| Chen Yu | 9.9% | |||
| BlackRock, Inc. 13G | 7.8% |
10/27/2026
Event 9/30/2026
|
||
|
ADAR1 Capital Management, LLC
13G
|
5.8% |
8/14/2026
Event 6/30/2026
|
||
| ADAR1 Capital Management, LLC | 5.8% | |||
| Daniel Schneeberger | 5.8% | |||
|
RA Capital Management, L.P.
13G
|
5.8% |
6/3/2026
Event 5/27/2026
|
||
| RA Capital Management, L.P. | 5.8% | |||
| Peter Kolchinsky | 5.8% | |||
| Rajeev Shah | 5.8% | |||
| RA Capital Healthcare Fund, L.P. | 5.8% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
|
Deep Track Capital, LP
13G/A
|
0% |
2/14/2025
Event 12/31/2024
|
||
| Deep Track Capital, LP | 0% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 0% | |||
| David Kroin | 0% | |||
| Vanguard Group Inc 13G/A | 0% |
3/26/2026
Event 3/13/2026
|
||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 224 | 139 M | $356M |
| 2026 Q2 | 221 | 119 M | $386M |
| 2026 Q1 | 212 | 51.8 M | $128M |
| 2025 Q4 | 203 | 49.9 M | $102M |
| 2025 Q3 | 200 | 43.0 M | $149M |
| 2025 Q2 | 198 | 41.3 M | $90.9M |
| 2025 Q1 | 198 | 44.0 M | $51.0M |
| 2024 Q4 | 208 | 51.1 M | $64.8M |
| 2024 Q3 | 231 | 55.1 M | $221M |
| 2024 Q2 | 238 | 56.4 M | $263M |
| 2024 Q1 | 228 | 67.9 M | $504M |
| 2023 Q4 | 229 | 58.8 M | $596M |
| 2023 Q3 | 225 | 61.7 M | $481M |
| 2023 Q2 | 241 | 62.8 M | $517M |
| 2023 Q1 | 237 | 53.0 M | $384M |
| 2022 Q4 | 254 | 54.0 M | $481M |
| 2022 Q3 | 270 | 48.3 M | $594M |
| 2022 Q2 | 263 | 47.5 M | $566M |
| 2022 Q1 | 261 | 45.4 M | $866M |
| 2021 Q4 | 309 | 51.1 M | $1.37B |
| 2021 Q3 | 329 | 52.4 M | $2.18B |
| 2021 Q2 | 324 | 52.2 M | $2.98B |
| 2021 Q1 | 317 | 53.2 M | $2.25B |
| 2020 Q4 | 320 | 53.0 M | $3.75B |
| 2020 Q3 | 244 | 55.2 M | $1.57B |
| 2020 Q2 | 243 | 54.4 M | $1.63B |
| 2020 Q1 | 203 | 45.8 M | $1.02B |
| 2019 Q4 | 234 | 45.8 M | $1.36B |
| 2019 Q3 | 189 | 45.0 M | $1.02B |
| 2019 Q2 | 196 | 40.0 M | $990M |
| 2019 Q1 | 205 | 37.5 M | $917M |
| 2018 Q4 | 197 | 34.5 M | $784M |
| 2018 Q3 | 201 | 33.8 M | $1.08B |
| 2018 Q2 | 218 | 32.6 M | $1.17B |
| 2018 Q1 | 201 | 31.2 M | $1.03B |
| 2017 Q4 | 153 | 30.4 M | $934M |
| 2017 Q3 | 119 | 29.1 M | $698M |
| 2017 Q2 | 111 | 29.2 M | $490M |
| 2017 Q1 | 99 | 27.5 M | $614M |
| 2016 Q4 | 84 | 23.5 M | $381M |
| 2016 Q3 | 75 | 22.2 M | $299M |
| 2016 Q2 | 68 | 22.6 M | $550M |
| 2016 Q1 | 50 | 18.2 M | $625M |